Summary:
Crestone, Inc. / “A PHASE 2, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRS3123 COMPARED WITH ORAL VANCOMYCIN IN ADULTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION”
Qualified Participants Must:
• Have a primary episode or first recurrence of Clostridioides difficile (C. difficile) infection
•
Diarrhea in the last 24 hours
•
Ages 18 or older
Qualified Participants May Receive:
$50.00 for each visit
$25.00 for each telephone contact
All study medication, assessments and examinations are free to the participants.